Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s share price traded up 5.9% during mid-day trading on Tuesday . The stock traded as high as $58.17 and last traded at $57.40, with a volume of 671,322 shares trading hands. The stock had previously closed at $54.22.

Several equities analysts have issued reports on the company. Jefferies Group reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Sunday, July 17th. Canaccord Genuity reissued a “buy” rating and issued a $120.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, July 15th. Credit Suisse Group AG reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, July 12th. Wedbush reissued an “outperform” rating and issued a $92.00 price target (down previously from $99.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Finally, Zacks Investment Research raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th. Three analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $98.09.

The company’s market capitalization is $2.37 billion. The firm’s 50-day moving average is $54.56 and its 200 day moving average is $62.41.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.29) by $0.06. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.63) EPS. On average, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post ($5.84) EPS for the current year.

In other Ultragenyx Pharmaceutical news, insider Sunil Agarwal sold 650 shares of the company’s stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $66.00, for a total value of $42,900.00. Following the completion of the transaction, the insider now directly owns 7,111 shares in the company, valued at approximately $469,326. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $59.95, for a total transaction of $1,199,000.00. Following the completion of the transaction, the chief executive officer now owns 526,704 shares of the company’s stock, valued at $31,575,904.80. The disclosure for this sale can be found here.

A number of institutional investors have made changes to their positions in the stock. Trexquant Investment LP acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at about $1,010,000. GSA Capital Partners LLP boosted its position in shares of Ultragenyx Pharmaceutical by 12.2% in the fourth quarter. GSA Capital Partners LLP now owns 11,188 shares of the biopharmaceutical company’s stock valued at $1,255,000 after buying an additional 1,218 shares during the period. Russell Frank Co boosted its position in shares of Ultragenyx Pharmaceutical by 425.8% in the fourth quarter. Russell Frank Co now owns 13,523 shares of the biopharmaceutical company’s stock valued at $1,529,000 after buying an additional 10,951 shares during the period. Mutual of America Capital Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 1.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 33,497 shares of the biopharmaceutical company’s stock valued at $3,758,000 after buying an additional 497 shares during the period. Finally, Swiss National Bank boosted its position in shares of Ultragenyx Pharmaceutical by 1.4% in the fourth quarter. Swiss National Bank now owns 35,367 shares of the biopharmaceutical company’s stock valued at $3,967,000 after buying an additional 500 shares during the period.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.